First and only liquid embolic approved for both peripheral arterial bleeds and hypervascular tumors

Materializing Solutions

Developing Next generation Resorbable Embolics

Instylla is a privately held company based in Burlington, MA, focused on developing novel resorbable embolic agents to advance interventional radiology, with initial clinical applications in interventional oncology.

"What sets Embrace HES apart is its safety profile and controlled delivery. In the HALT Study, I saw firsthand how its design features help minimize non-target embolization and allow you to adjust the embolic placement. I'm looking forward to what this expanded indication could mean for patients."

"When treating an arterial bleed, you need an embolic solution that can reach the source of bleeding while providing precise control. Embrace HES allows you to tailor your approach to the anatomy, achieving either distal or proximal embolization with a single embolic agent. Its novel design also allows you to maintain microcatheter access after embolization, unlike many currently available liquid embolics. This combination of control, versatility, and preserved access makes it a valuable new option for interventional radiologists."

"I am excited to have this wonderful new tool in the IR repertoire."

"We are thrilled to be part of such an important milestone in the field of embolization for hypervascular tumors. We look forward to witnessing the many possibilities that the Embrace liquid embolic will bring to the cancer embolization space."

"Embrace is next level! It allows deep hypervascular tumor penetration for total blood flow occlusion. Plus, it resorbs with time so nothing is left behind and no further treatment option is excluded. I love it!"

Solutions & Clinical Results

Embrace Hydrogel Embolic System (HES) is the only non-adhesive liquid embolic penetrating to the capillary level for proven targeted hypervascular tumor treatment and favorable target lesion response without recanalization.

The Instylla HES Hypervascular Tumor Study: A prospective, randomized, multicenter, subject and evaluator blinded pivotal trial.

Primary Safety and Effectiveness Endpoints Met on the Instylla HES Hypervascular Tumor study evaluating the Embrace HES against Standard of Care, Transcatheter Arterial Embolization (TAE)/ Transcatheter Arterial Chemoembolization (cTACE) procedures

The Tembo™ Embolic System consists of dry, irregularly shaped, resorbable gelatin particles designed for use in the embolization of hypervascular tumors and occlusion of blood vessels in the peripheral vasculature.

Latest News

Instylla’s Embrace^® Hydrogel Embolic System Receives FDA Approval for Peripheral Arterial Bleeds

First and Only Liquid Embolic Approved for Both Peripheral Arterial Bleeds and Hypervascular Tumors Supported by Two Prospective, Multicenter Pivotal Clinical Trials BURLINGTON, Mass., October 29th, 2026 – Instylla, Inc., a privately held company advancing resorbable embolics for peripheral vascular

Instylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System

Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., January 28th, 2026 – Instylla, Inc., a privately held company developing novel resorbable

Instylla Gains U.S. FDA Premarket Approval for Embrace™ Hydrogel Embolic System

First and Only Liquid Embolic Approved for Hypervascular Tumor Embolization Supported by a Prospective, Randomized, Controlled, Clinical Trial BEDFORD, Mass., August 7, 2025 – Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval

First and only liquid embolic approved for both peripheral arterial bleeds and hypervascular tumors